Maintenance Olaparib Found to Provide a PFS Benefit in Advanced Ovarian Cancer
The benefit was seen in an all-comers population, according to the presenters at ESMO Congress 2019.
Diagnosis & Disease Information
Kegel Exercises May Prevent Incontinence Associated With Prostate Cancer
Researchers sought to determine if practicing Kegel exercises, a common pelvic-floor exercise, could prevent urinary and fecal incontinence in patients with prostate cancer.
Can Plasma-Based NGS be Routinely Used to Select Treatment in Advanced NSCLC?
This study provided evidence suggesting that advanced NSCLC characterized by a genomic alterations in both STK11 and KRAS may not respond well to immunotherapy.
Additional Support for Benefit of 21-Gene Assay in Early-Stage Breast Cancer: A Subgroup Analysis of TAILORx
In TAILORx, 84% of patients with a high recurrence score were treated with chemotherapy containing a taxane and/or an anthracycline prior to endocrine therapy.
Single-Agent Immunotherapies Carry Different irAE Risks
“Despite a lack of head-to-head trials, there is a perception that irAE profiles are
comparable between agents,” the abstract authors wrote.
Immunotherapy irAEs Associated With Hospitalizations, Treatment Discontinuation
More than 15,000 distinct irAEs were found for 13,030 patients.
Blood Test May Potentially Replace Invasive Biopsy for Certain Patients With Lung Cancer: Results of BFAST
Liquid biopsy can be used to detect a complex type of driver mutation, called ALK, in patients with NSCLC.
Pembrolizumab Does Not Outperform Chemotherapy in Mesothelioma
While pembrolizumab was not superior to chemotherapy, survival times were similar, suggesting immunotherapy might offer an alternative to chemotherapy.
Palbociclib, Capecitabine Regimens Offer Similar Patient-Reported Quality-of-Life Outcomes in Metastatic HR-Positive Breast Cancer
Results of the YoungPearl study revealed that patient-reported QoL scores were high for palbociclib plus endocrine therapy.
Abemaciclib Plus Fulvestrant Improved Survival in Patients with HR+, HER2- Advanced Breast Cancer
Results of MONARCH-2 showed a statistically significant and clinically meaningful improvement in overall survival with abemaciclib plus fulvestrant.
- Loading...
Loading...
Loading... 
Loading...